Status:
COMPLETED
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Iqvia Pty Ltd
Conditions:
COVID-19
SARS-CoV-2
Eligibility:
All Genders
18-130 years
Phase:
PHASE3
Brief Summary
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Detailed Description
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated v...
Eligibility Criteria
Inclusion
- Increased risk of SARS-CoV-2 infection
- Medically stable
Exclusion
- confirmed or suspected immunosuppressive or immunodeficient state
- significant disease, disorder, or finding
- Prior or concomitant vaccine therapy for COVID-19
Key Trial Info
Start Date :
August 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2023
Estimated Enrollment :
32450 Patients enrolled
Trial Details
Trial ID
NCT04516746
Start Date
August 28 2020
End Date
February 10 2023
Last Update
February 5 2024
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States, 85018
2
Research Site
Scottsdale, Arizona, United States, 85258
3
Research Site
Little Rock, Arkansas, United States, 72212
4
Research Site
Berkeley, California, United States, 94705